Alnylam Launches “Alnylam P5x25” Strategy For Planned Transition To A Top Five Biotech In Market Capitalization Over Next Five Years
January 10, 2021 at 15:08 PM EST
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced its new five-year strategy, “Alnylam P5x25,” which is focused on the company’s transition to a top-5 biotech (measured by market capitalization) in the next five years.
